missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ MED29 Polyclonal Antibody

Description
This target displays homology in the following species: Cow: 100%; Dog: 100%; Horse: 100%; Human: 100%; Mouse: 100%; Pig: 100%; Rabbit: 100%; Rat: 100%; Zebrafish: 79%.
In mammalian cells, transcription is regulated in part by high molecular weight co-activating complexes that mediate signals between transcriptional activators and RNA polymerase II (Pol II). The mediator complex is one such multi-protein structure that functions as a bridge between regulatory proteins and Pol II, thereby regulating Pol II-dependent transcription. Med29 (mediator complex subunit 29), also known as IXL (intersex-like), is a 200 amino acid nuclear protein and component of the mediator complex. Widely expressed in embryo and adult tissue, Med29 is considered a novel amplification target gene in pancreatic cancer and is encoded by a gene that maps to human chromosome 19q13.2. Chromosome 19 consists of over 63 million bases, houses approximately 1,400 genes and is recognized for having the greatest gene density of the human chromosomes.
Specifications
Specifications
| Antigen | MED29 |
| Applications | Western Blot |
| Classification | Polyclonal |
| Concentration | 0.5 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 2% sucrose and 0.09% sodium azide |
| Gene | MED29 |
| Gene Accession No. | Q9DB91 |
| Gene Alias | 2810405O22Rik; AU020902; chunp6869; DKFZp434H247-like protein; intersex-like protein; ixl; ixl protein; MED2; MED29; Mediator complex subunit 29; mediator of RNA polymerase II transcription subunit 29; RGD1311009; similar to Homo sapiens DKFZp434H247 protein; zgc:109789 |
| Gene Symbols | MED29 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?